Tanimilast
Small moleculeexperimental
Clinical trial activity
17 trials · 14 clinical orgs · 0 marketing orgs
Phase 1
9
Phase 2
8
Phase 3
2
Phase 4
0
Earliest trial started Jul 1, 2011 (NCT01703052)
Timeline
Indications
Mechanism of action
- Phosphodiesterase 4AINHIBITOR
PDE4A inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- 3,5-dichloro-4-(2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(3-(cyclopropylmethoxy)-4-(methylsulfonamido)benzoyloxy)ethyl)pyridine 1-oxide
- chf6001
- chf6001
- chf6001
- chf 6001
- chf 6001
- chf-6001
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06900816 | Phase 2 | Mar 28, 2025 | Chiesi, Comac Medical |
| NCT06892756 | Phase 1 | Mar 18, 2025 | Chiesi, Comac Medical |
| NCT06395610 | Phase 1 | Mar 28, 2024 | Chiesi |
| NCT06029595 | Phase 2 | Nov 28, 2023 | Chiesi, University of Rostock |
| NCT05431426 | Phase 1 | Jul 29, 2022 | Chiesi |
| NCT05373953 | Phase 1 | May 5, 2022 | Chiesi |
| NCT04636801 | Phase 3 | Jul 14, 2021 | Chiesi, LungenClinic Grosshansdorf |
| NCT04636814 | Phase 3 | Jul 12, 2021 | Chiesi, Cornell University |
| NCT04756960 | Phase 1 | Mar 10, 2021 | Chiesi |
| NCT04739774 | Phase 1 | Feb 22, 2021 | Chiesi |
| NCT02986321 | Phase 2 | Dec 1, 2016 | Chiesi, University of Manchester |
| NCT03004417 | Phase 2 | Oct 1, 2016 | Chiesi, SGS Life Sciences, University of Manchester |
| NCT03004495 | Phase 1 | Jan 1, 2016 | Chiesi, IQVIA |
| NCT02386761 | Phase 1 | Nov 1, 2014 | Chiesi, Quotient |
| NCT01689571 | Phase 2 | Oct 1, 2012 | Chiesi, Hammersmith Medicines Research, University of Manchester |
| NCT01730404 | Phase 2 | Oct 1, 2012 | Celerion, Chiesi, Freeman Health System, Parexel, University of Manchester, University of Nottingham |
| NCT01703052 | Phase 1 | Jul 1, 2011 | Chiesi, Quotient |
Showing 17 of 17 trials
Page 1 / 1
Organizations
Research & Development (14)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Chiesi | For profit | 17 | 17 | 3 | 2011 |
| University of Manchester | Academic/Hospital | 4 | 0 | 1 | 2012 |
| Comac Medical | For profit | 2 | 0 | 2 | 2025 |
| Quotient | For profit | 2 | 0 | 1 | 2011 |
| Celerion | For profit | 1 | 0 | 1 | 2012 |
| Cornell University | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Freeman Health System | Academic/Hospital | 1 | 0 | 1 | 2012 |
| Hammersmith Medicines Research | For profit | 1 | 0 | 1 | 2012 |
| IQVIA | For profit | 1 | 0 | 1 | 2016 |
| LungenClinic Grosshansdorf | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Parexel | For profit | 1 | 0 | 1 | 2012 |
| SGS Life Sciences | For profit | 1 | 0 | 1 | 2016 |
| University of Nottingham | Academic/Hospital | 1 | 0 | 1 | 2012 |
| University of Rostock | Academic/Hospital | 1 | 0 | 1 | 2023 |
14 organizations
Page 1 / 1